Burosumab

We look into promising findings from clinical trials regarding Burosumab, a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia. With us are Erik Imel, MD from the Indiana University School of Medicine and Suzanne Marie Jan De Beur, MD from Johns Hopkins University School of Medicine.

• ENDO 2019 Abstract – Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
• ENDO 2019 Abstract – Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
• Endocrine Reviews article – X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment
• Journal of the Endocrine Society article – Nephrocalcinosis and Nephrolithiasis in X-Linked Hypophosphatemic Rickets: Diagnostic Imaging and Risk Factors
• Journal of the Endocrine Society article – The Lifelong Impact of X-Linked Hypophosphatemia: Results from a Burden of Disease Survey
• Download m4a
• Download mp3

Subscribe

Stay up to date by copying the following into your podcast player:

https://www.endocrine.org/-/media/endosociety/files/podcasts/enp.xml

Or you can find us on the following streaming services:

All Episodes